Sudeep Pharma Ltd
Sudeep Pharma Ltd (SUDEEPPHRM) last reported results for the quarter ended Jun 2026, with sales of ₹158 crore and net profit of ₹41 crore. The stock last traded at ₹1,179, a market capitalisation of ₹13,318 crore, on a P/E of 73.0. Over the past 52 weeks the stock has ranged between ₹524 and ₹1,378. Figures are as of 6 Oct 2026 and are not real time.
Sudeep Pharma Ltd share price and key metrics
- Current price
- ₹1,179
- Market cap
- ₹13,318 cr
- Stock P/E
- 73.0
- Book value
- ₹78.2
- ROE
- 25.2%
- ROCE
- 28.2%
- Dividend yield
- 0.13%
- 52w high / low
- 1378/524
Metrics as of 6 Oct 2026. Not real time.
Track Sudeep Pharma Ltd
Cruxal reads every Sudeep Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sudeep Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 14%
- TTM
- 24%
- 10 Years
- %
- 5 Years
- 39%
- 3 Years
- 40%
- TTM
- 20%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 32%
- 3 Years
- 32%
- Last Year
- 25%
Sudeep Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹158 cr, up 26.4% from ₹125 cr a year earlier. Net profit was ₹41 cr, up 32.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS (₹) | 128.13 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sudeep Pharma Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Operating profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Net profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS (₹) | 128.02 | 236.60 | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 | 16.83 |
TTM is the trailing twelve months to the most recent quarter.
Sudeep Pharma Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Total liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
As reported by the company. Total assets equal total liabilities by construction.
Sudeep Pharma Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from investing | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from financing | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net cash flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free cash flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO / operating profit | 62% | 104% | 22% | 78% | 60% | 47% | 56% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sudeep Pharma Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 36% | 36% | 33% | 49% | 36% | 28% |
| Debtor days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash conversion cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working capital days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sudeep Pharma Ltd shareholding pattern
Promoters held 76.16% at Jun 2026, broadly unchanged since Dec 2025. FIIs 1.81% and DIIs 15.64%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 76.16% | 76.16% | 76.16% |
| FIIs | 1.67% | 1.55% | 1.81% |
| DIIs | 17.59% | 18.11% | 15.64% |
| Public | 4.57% | 4.18% | 6.39% |
| No. of shareholders | 43,599 | 36,503 | 35,695 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sudeep Pharma Ltd corporate filings
- Submission of Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulation as on 30.09.2026Company Updatelow impact
- Sudeep Pharma Limited announces ceasing of Managing Director Mr. Sendhil Pani due to contractual completion, with no immediate financial impact disclosedCompany Updatelow impact
Cruxal's analysis: Sudeep Pharma Limited has formally announced the cessation of its Managing Director, Mr…
Read the full analysis - Intimation for Closure of Trading window w.e.f. 1st October 2026Insider Trading / SASTlow impact
- Sudeep Pharma Ltd to participate in Nuvama Emerging India CEO Forum 2026Company Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has announced that company officials will attend the Nuvama Emerging…
Read the full analysis - Sudeep Pharma Ltd cancels scheduled investor and analyst meetingCompany Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has issued an intimation regarding the cancellation of a previously…
Read the full analysis - Sudeep Pharma schedules investor and analyst plant visit in Gujarat for September 23-24, 2026Company Updatelow impact
Cruxal's analysis: Sudeep Pharma has announced a plant visit for analysts and investors to be held in…
Read the full analysis - Sudeep Pharma Reports 27% YoY Revenue Growth in Q1 FY27; Advances Battery Material Expansion PlansCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited reported a strong start to FY27 with consolidated revenue of INR…
Read the full analysis - Sudeep Pharma Ltd issues general updateCompany Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has released a general update filing dated August 6, 2026. The…
Read the full analysis - Sudeep Pharma Limited uploads audio recording of Q1 FY27 earnings callCompany Updatelow impact
Cruxal's analysis: Sudeep Pharma Limited has formally filed the audio recording of its Q1 FY27 earnings call…
Read the full analysis - Sudeep Pharma Limited concludes 37th AGM; shareholders approve ESOP Scheme 2025 and director remuneration changesAGM/EGMmedium impact
Cruxal's analysis: Sudeep Pharma Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Sudeep Pharma Ltd submits newspaper publication of financial results for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Sudeep Pharma Reports Strong Q1 FY27 Performance with 27% YoY Revenue Growth and Strategic Progress in Battery MaterialsCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Sudeep Pharma Reports Strong Q1 FY27 Performance with 27% YoY Revenue Growth and Strategic Progress in Battery MaterialsCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Sudeep Pharma Limited Reports Strong Q1 FY27 Performance with 27% YoY Revenue Growth and Strategic Progress in Battery MaterialsCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Sudeep Pharma Reports Strong Q1 FY27 Consolidated Earnings with 27% Revenue and 30% PAT Growth YoYBoard Meetinghigh impact
Cruxal's analysis: Sudeep Pharma Limited has announced robust consolidated financial results for the first…
Read the full analysis - Sudeep Pharma Reports Highest-Ever Revenue of INR 642.3 Crore in FY26, Driven by 63% Growth in Specialty Ingredients and Strategic Expansion into Advanced Battery MaterialsAGM/EGMhigh impact
Cruxal's analysis: Sudeep Pharma Limited has announced robust financial results for the fiscal year 2025-26…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.